Literature DB >> 28362653

Population-based organized cervical cancer screening pilot program in France.

Françoise F Hamers1, Nicolas Duport, Nathalie Beltzer.   

Abstract

In France, cervical cancer screening is recommended every 3 years for women aged 25-65 years. With the exception of a few local organized programs, screening is mainly opportunistic. In view of setting up a nationwide population-based organized screening program, a pilot intervention was implemented in nine geographic areas using a common protocol. Women aged 25-65 years who had not undergone a cytological screening in the past 3 years were invited for screening during 2010-2012 and reminded up to 1 year after the initial invitation. Cytological results and follow-up data were collected up to the end of 2014 for all women screened irrespective of whether spontaneously or following invitation. Aggregate data were centralized nationally. Among the 2.4 million women from the total target population aged 25-65 years, 1.3 million were invited for screening. The overall screening coverage during 2010-2012 was 62.3%, with wide variations across geographic areas, ranging from 41.6 to 72.5%. Initial invitations and reminders enabled nearly 280 000 women to be screened, corresponding to an estimated increase in coverage of 12% points. Overall, 4.2% of the women screened had an abnormal smear. A total of 5180 high-grade cervical precancers and 323 invasive cervical cancers were reported, corresponding to detection rates of, respectively, 623 and 39 per 100 000 women screened 3-yearly. This study indicates that such organized screening may markedly improve the uptake of cervical cancer screening. On the basis of this pilot program, nationwide organized cervical cancer screening is currently being rolled out in France.

Entities:  

Mesh:

Year:  2018        PMID: 28362653     DOI: 10.1097/CEJ.0000000000000365

Source DB:  PubMed          Journal:  Eur J Cancer Prev        ISSN: 0959-8278            Impact factor:   2.497


  7 in total

1.  Social Inequalities in Participation in Cervical Cancer Screening in a Metropolitan Area Implementing a Pilot Organised Screening Programme (Paris Region, France).

Authors:  Celine Audiger; Thomas Bovagnet; Julia Bardes; Gaelle Abihsera; Jerome Nicolet; Michel Deghaye; Audrey Bochaton; Gwenn Menvielle
Journal:  Int J Public Health       Date:  2022-07-04       Impact factor: 5.100

2.  Towards equity in organised cancer screening: the case of cervical cancer screening in France.

Authors:  Sylviane Darquy; Grégoire Moutel; Odile Jullian; Stéphanie Barré; Nathalie Duchange
Journal:  BMC Womens Health       Date:  2018-11-26       Impact factor: 2.809

3.  HPV-vaccination and cancer cervical screening in 53 WHO European Countries: An update on prevention programs according to income level.

Authors:  Emma Altobelli; Leonardo Rapacchietta; Valerio F Profeta; Roberto Fagnano
Journal:  Cancer Med       Date:  2019-04-16       Impact factor: 4.452

4.  Updated evidence-based recommendations for cervical cancer screening in France.

Authors:  Françoise F Hamers; Anne-Isabelle Poullié; Marc Arbyn
Journal:  Eur J Cancer Prev       Date:  2022-05-01       Impact factor: 2.164

5.  Health economic evaluation of an mRNA high-risk human papillomavirus (HR-HPV) assay versus a DNA HR-HPV assay for the proposed French cervical screening programme.

Authors:  Caroline A Dombrowski; Georgie Mf Weston; Pr Philippe Descamps; Pr Jacques Izopet; Elisabeth J Adams; Elisabeth Adams
Journal:  Medicine (Baltimore)       Date:  2022-07-22       Impact factor: 1.817

6.  Organised screening for cervical cancer in France: a cost-effectiveness assessment.

Authors:  Stéphanie Barré; Marc Massetti; Henri Leleu; Frédéric De Bels
Journal:  BMJ Open       Date:  2017-10-06       Impact factor: 2.692

7.  Gynaecological cancer in Caribbean women: data from the French population-based cancer registries of Martinique, Guadeloupe and French Guiana (2007-2014).

Authors:  Clarisse Joachim; Jacqueline Véronique-Baudin; Laure Desroziers; Édouard Chatignoux; Sophie Belliardo; Juliette Plenet; Jonathan Macni; Stephen Ulric-Gervaise; Jessica Peruvien; Bernard Bhakkan-Mambir; Jacqueline Deloumeaux
Journal:  BMC Cancer       Date:  2020-07-10       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.